×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OPK – opko health, inc. (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OPK
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/27
05:27 pm
opk
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings? [Yahoo! Finance]
Low
Report
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings? [Yahoo! Finance]
4/22
08:00 am
opk
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
Neutral
Report
OPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell Lymphomas
4/21
04:05 pm
opk
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
Low
Report
OPKO Health to Report First Quarter 2026 Financial Results on April 28, 2026
4/13
04:33 pm
opk
GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026 [Yahoo! Finance]
Neutral
Report
GeneDx to Report First Quarter 2026 Financial Results on Monday, May 4, 2026 [Yahoo! Finance]
4/8
08:00 am
opk
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
Low
Report
OPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19
3/24
11:12 am
opk
Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target [Yahoo! Finance]
Low
Report
Craig-Hallum Reaffirms Buy on GeneDx (WGS) With $153 Price Target [Yahoo! Finance]
3/24
06:13 am
opk
Previvor Edge Expands Platform to Deliver Personalized Clinical-Grade Cancer Risk Profiles and Interactive Prevention Plans [TheStreet.com]
Low
Report
Previvor Edge Expands Platform to Deliver Personalized Clinical-Grade Cancer Risk Profiles and Interactive Prevention Plans [TheStreet.com]
3/23
09:35 pm
opk
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? [Yahoo! Finance]
Low
Report
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/20
04:25 pm
opk
Form 4 OPKO HEALTH, INC. For: Mar 20 Filed by: PAGANELLI JOHN A
Neutral
Report
Form 4 OPKO HEALTH, INC. For: Mar 20 Filed by: PAGANELLI JOHN A
3/20
04:17 pm
opk
Form 4 OPKO HEALTH, INC. For: Mar 18 Filed by: UPPALURI SUBBARAO V
Low
Report
Form 4 OPKO HEALTH, INC. For: Mar 18 Filed by: UPPALURI SUBBARAO V
3/20
04:10 pm
opk
Form 3 OPKO HEALTH, INC. For: Mar 18 Filed by: UPPALURI SUBBARAO V
Low
Report
Form 3 OPKO HEALTH, INC. For: Mar 18 Filed by: UPPALURI SUBBARAO V
3/19
04:50 pm
opk
Form 8-K OPKO HEALTH, INC. For: Mar 18
Medium
Report
Form 8-K OPKO HEALTH, INC. For: Mar 18
2/26
04:16 pm
opk
Form 10-K OPKO HEALTH, INC. For: Dec 31
Low
Report
Form 10-K OPKO HEALTH, INC. For: Dec 31
2/26
04:10 pm
opk
Form 8-K OPKO HEALTH, INC. For: Feb 26
Neutral
Report
Form 8-K OPKO HEALTH, INC. For: Feb 26
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/5
OPKO Health's BioReference Laboratories to Introduce Coronavirus Disease (COVID-19) Test
29.2%
4/20 Form 4 Opko Health, Inc. For: Apr 17 Filed by: FROST PHILLIP MD ET AL 16.5%
3/17 OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19) 13.1%
3/4 Form 4 Opko Health, Inc. For: Mar 03 Filed by: Frost Gamma Investments Trust 12.2%
3/13 Form 4 Opko Health, Inc. For: Mar 12 Filed by: Japour Anthony J 11.8%
4/6 Form 4 Opko Health, Inc. For: Apr 03 Filed by: FROST PHILLIP MD ET AL 11.6%
6/28 Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test 9.9%
4/8 Form 4 Opko Health, Inc. For: Apr 07 Filed by: Frost Gamma Investments Trust 7.8%
9/23 Form 8-K Opko Health, Inc. For: Sep 21 6.5%
3/10 Opko Health Inc. (NASDAQ: OPK) had its price target raised by analysts at Piper Sandler from to . 6.2%
4/20 Form 4 Opko Health, Inc. For: Apr 17 Filed by: FROST PHILLIP MD ET AL 16.5%
3/17 OPKO Health's BioReference Laboratories and NYC Health + Hospitals Enter into Laboratory Collaboration to Provide Testing for Coronavirus Disease 2019 (COVID-19) 13.1%
3/4 Form 4 Opko Health, Inc. For: Mar 03 Filed by: Frost Gamma Investments Trust 12.2%
3/13 Form 4 Opko Health, Inc. For: Mar 12 Filed by: Japour Anthony J 11.8%
4/6 Form 4 Opko Health, Inc. For: Apr 03 Filed by: FROST PHILLIP MD ET AL 11.6%
6/28 Novitas Issues Proposed Local Coverage Determination for the 4Kscore® Test 9.9%
4/8 Form 4 Opko Health, Inc. For: Apr 07 Filed by: Frost Gamma Investments Trust 7.8%
9/23 Form 8-K Opko Health, Inc. For: Sep 21 6.5%
3/10 Opko Health Inc. (NASDAQ: OPK) had its price target raised by analysts at Piper Sandler from to . 6.2%
TOP News Decliners
3/9
Edited Transcript of OPK earnings conference call or presentation 26-Feb-20 9:30pm GMT [Yahoo! Finance News]
-26.0%
5/7 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.060 ActVsEst (0.080) - Miss -14.3%
10/24 OPKO Health, Inc. Announces Pricing of its Offering of Common Stock -14.3%
10/24 Form 424B5 Opko Health, Inc. -14.2%
3/13 Coronavirus activity roundup - healthcare [Seeking Alpha] -11.6%
3/7 Opko Health Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at Piper Sandler. -10.5%
3/20 Form 4 Opko Health, Inc. For: Mar 19 Filed by: Frost Gamma Investments Trust -8.5%
10/21 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency -7.8%
11/5 OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results -7.5%
5/13 Form 4 Opko Health, Inc. For: May 10 Filed by: FROST PHILLIP MD ET AL -6.7%
5/7 Q1/2019 3/31/2019 EPS -0.140 ZacksConsensus -0.060 ActVsEst (0.080) - Miss -14.3%
10/24 OPKO Health, Inc. Announces Pricing of its Offering of Common Stock -14.3%
10/24 Form 424B5 Opko Health, Inc. -14.2%
3/13 Coronavirus activity roundup - healthcare [Seeking Alpha] -11.6%
3/7 Opko Health Inc. (NASDAQ: OPK) had its "buy" rating re-affirmed by analysts at Piper Sandler. -10.5%
3/20 Form 4 Opko Health, Inc. For: Mar 19 Filed by: Frost Gamma Investments Trust -8.5%
10/21 OPKO and Pfizer Announce Positive Phase 3 Top-Line Results for Somatrogon, an Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency -7.8%
11/5 OPKO Health Reports 2019 Third Quarter Business Highlights and Financial Results -7.5%
5/13 Form 4 Opko Health, Inc. For: May 10 Filed by: FROST PHILLIP MD ET AL -6.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: